Frontier Capital Management Co. LLC cut its stake in Zoetis Inc (NYSE:ZTS) by 6.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,998,278 shares of the company’s stock after selling 142,311 shares during the quarter. Zoetis makes up 1.1% of Frontier Capital Management Co. LLC’s portfolio, making the stock its 13th biggest holding. Frontier Capital Management Co. LLC owned 0.41% of Zoetis worth $143,956,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Zoetis by 2.8% in the second quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock worth $2,099,379,000 after acquiring an additional 910,265 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of Zoetis by 1.5% in the third quarter. Janus Henderson Group PLC now owns 5,893,853 shares of the company’s stock worth $375,792,000 after acquiring an additional 84,767 shares during the last quarter. Northern Trust Corp increased its stake in shares of Zoetis by 1.2% in the second quarter. Northern Trust Corp now owns 5,533,313 shares of the company’s stock worth $345,168,000 after acquiring an additional 63,849 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Zoetis by 1.5% in the third quarter. Legal & General Group Plc now owns 2,400,106 shares of the company’s stock worth $153,025,000 after acquiring an additional 34,747 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Zoetis by 1.6% in the second quarter. UBS Asset Management Americas Inc. now owns 1,973,820 shares of the company’s stock worth $123,127,000 after acquiring an additional 31,211 shares during the last quarter. 93.14% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have recently weighed in on ZTS shares. BMO Capital Markets set a $65.00 price target on shares of Zoetis and gave the stock a “hold” rating in a research note on Wednesday, October 25th. Zacks Investment Research downgraded shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target on the stock. in a research note on Saturday, January 13th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research note on Tuesday, October 24th. BidaskClub downgraded shares of Zoetis from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Finally, Cowen set a $80.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, November 17th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $73.72.
Zoetis Inc (ZTS) traded up $1.23 during trading on Thursday, reaching $76.77. 2,769,500 shares of the company’s stock traded hands, compared to its average volume of 2,426,191. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The firm has a market capitalization of $37,140.00, a P/E ratio of 40.41, a price-to-earnings-growth ratio of 1.88 and a beta of 1.06. Zoetis Inc has a 52-week low of $52.00 and a 52-week high of $77.03.
Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.52 earnings per share. equities research analysts forecast that Zoetis Inc will post 2.37 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be given a $0.126 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 annualized dividend and a dividend yield of 0.66%. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s dividend payout ratio (DPR) is currently 22.11%.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.